GET DAILY SIGNALSWhy Is iRhythm Holdings (IRTC) Stock Down -32.72% Today?
Key Takeaways
- Shares of IRTC plunged roughly 32.72% intraday, trading near $87.59 versus a prior close of $130.19.
- The primary catalyst was the company's announcement that it no longer plans to submit its Zio MTC mobile cardiac telemetry device to the FDA this year, pushing its next-generation algorithm submission into 2027.
- Secondary pressure came from mixed third-quarter results, flat Zio AT revenue, and a wave of analyst downgrades and price-target cuts.
- The sell-off diverged sharply from the broader healthcare and med-tech complex, reflecting a company-specific regulatory timeline setback rather than broad sector weakness.
- Traders are watching for updated FDA submission timelines, 2027 guidance details, and any stabilization in Zio AT growth.
- For deeper analysis, explore our dedicated pages for Price Targets, Earnings, and Forecast.
- To see how AI-driven strategies are positioning across the market, explore Trending AI Robots.
Opening Summary
iRhythm Holdings, Inc. (IRTC) is a San Francisco–based digital healthcare company best known for its Zio line of wearable patch-based ambulatory cardiac monitoring devices, which help clinicians diagnose arrhythmias. The stock suffered a steep decline on Friday, falling approximately 32.72% to around $87.59 from a prior session close of $130.19. The sell-off was triggered by a regulatory setback: management disclosed on its earnings call that it would no longer file its Zio MTC device with the U.S. Food and Drug Administration in 2026, deferring its next-generation algorithm application to 2027.
Delayed FDA Submission for Zio MTC
The dominant driver behind the decline was the company's revised regulatory timeline. iRhythm said it no longer expects to submit its Zio MTC mobile cardiac telemetry device to the FDA this year and now anticipates filing its next-generation algorithm in 2027. Chief Executive Officer Quentin Blackford acknowledged the disappointment, stating that the company "did not perform as expected" and that the timeline has been adjusted multiple times. For a growth story built on expanding its cardiac-monitoring product portfolio, the postponement of a key FDA filing removes a near-term catalyst and raises questions about execution, prompting investors to reprice the shares.
Mixed Third-Quarter Results
The regulatory news overshadowed an otherwise mixed earnings report. Revenue rose 14.9% year over year to $221.6 million, roughly in line with consensus but slightly below some estimates. Demand for the flagship Zio Monitor remained robust, exceeding internal expectations. However, Zio AT revenue was essentially flat year over year and came in below management's targets, a source of incremental concern. GAAP results were also weighed down by a sizable one-time patent-litigation settlement charge, while adjusted profitability improved. The market, however, focused squarely on the delayed FDA filing and softer-than-expected dynamics in Zio AT.
Analyst Downgrades and Price-Target Cuts
The timeline setback triggered swift reactions from Wall Street. Citi downgraded the stock from Buy to Neutral and cut its price target from $157 to $124, describing the quarter as chaotic. BTIG maintained a more constructive stance but lowered its target from $185 to $170, citing the negative surprise in Zio AT. The combination of a regulatory delay and tempered sell-side views compounded the selling pressure, reinforcing the downward move throughout the session.
Market Context and Trading Activity
Trading activity was exceptionally heavy, with volume running well above the stock's typical daily average as investors repositioned following the earnings call. The decline was idiosyncratic: it did not track broader equity indices or the wider med-tech sector, signaling a company-specific repricing rather than a systemic market move. The sharp drop pushed shares through multiple technical support levels and well below recent moving averages, leaving the stock near its lowest levels in months and highlighting how quickly sentiment can shift when a key regulatory milestone slips.
What Comes Next for IRTC
Investors will be closely watching management's updated FDA submission timeline for Zio MTC and any additional color on the 2027 algorithm filing. Attention will also center on whether Zio AT returns to growth and whether the recently closed VitalConnect acquisition broadens the company's mobile cardiac telemetry portfolio as intended. Full-year 2026 revenue guidance was modestly raised to a midpoint of $892.5 million, but the path to restoring investor confidence now depends on delivering the regulatory milestones that were just delayed. Risks include further timeline slippage, integration challenges from the VitalConnect deal, and continued competitive and reimbursement pressures in cardiac monitoring.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots that cover thousands of tickers, including IRTC, each operating with distinct strategies, timeframes, performance metrics, and traded symbols. Because market conditions change, only the strongest current performers are featured in the curated Trending AI Robots section, giving traders a focused view of which automated strategies are adapting best right now. Explore the page to see how AI is navigating today's market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IRTC's RSI Indicator slumps oversold zone
The RSI Oscillator for IRTC moved into overbought territory on November 06, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for IRTC crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.
Following a +6.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where IRTC advanced for three days, in 254 of 321 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
IRTC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 198 of 241 cases where IRTC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 66 cases where IRTC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 74%.
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IRTC as a result. In 68 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
The Moving Average Convergence Divergence Histogram (MACD) for IRTC turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 39 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
IRTC moved below its 50-day moving average on November 06, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRTC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.990) is normal, around the industry mean (4.142). IRTC has a moderately low P/E Ratio (-214.810) as compared to the industry average of (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (4.398) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. IRTC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IRTC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of monitoring and diagnostic solutions for detection of cardiac arrhythmias
Industry MedicalNursingServices
Advertisement